A Phase 1, Open-Label, 6 Sequence, 3 Period, Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Relative Bioavailability Of 3 Palbociclib Formulations
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2018
Price : $35 *
At a glance
- Drugs Palbociclib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
- 03 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.